Literature DB >> 8927039

Long-term correction of STZ-diabetic rats after short-term i.p. VOSO4 treatment: persistence of insulin secreting capacities assessed by isolated pancreas studies.

P Poucheret1, R Gross, A Cadène, M Mantéguetti, J J Serrano, G Ribes, G Cros.   

Abstract

We have previously shown that 3 week oral VOSO4 treatment of streptozotocin (STZ, 60 mg/kg)-induced diabetic rats was able to correct diabetes for 13 weeks after treatment withdrawal. In the present study, we investigated whether a short-term (8 days) i.p. VOSO4 treatment was similarly able to reverse the diabetic state. Insulin secretory capacities were assessed at distance of treatment using the isolated pancreas preparation. Seven treatment-groups were performed: high dose VOSO4-treated diabetics (HVD, 1.3 mM/kg/8 days), food-restricted diabetics (FRD, food adjusted to HVD levels), low dose VOSO4-treated diabetes (LVD, 0.06 mM/kg/day), insulin-treated diabetics (ID, dose adjusted to normalize glycaemia) and VOSO4 (0.06 mM/kg/day) + insulin (dose adjusted to normalize glycaemia in the presence of vanadium)-treated diabetics (IVD), in addition to the corresponding untreated non-diabetic controls (C) and diabetics (D). Our results indicate that long-term correction of diabetes (a) can be obtained after an 8 day treatment using i.p. VOSO4 in diabetic animals retaining some degree of pancreatic function, (b) is not obtained with insulin treatment or food restriction although the association of VOSO4 and insulin was found beneficial, (c) can be prolonged in some individuals for at least 4 months, i.e. in conditions such that tissue vanadium concentrations had returned to values close to pre-treatment levels, (d) is associated with improved and in some cases normalized insulin secretion from isolated pancreas. The protective or corrective role of VOSO4 on diabetes-related pancreatic alterations, as well as the potential of the VOSO4-insulin association should be further studied in view of the possible use of vanadium derivatives in the treatment of diabetes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8927039     DOI: 10.1007/bf01075938

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  29 in total

1.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

2.  Oral vanadyl sulfate in treatment of diabetes mellitus in rats.

Authors:  S Ramanadham; J J Mongold; R W Brownsey; G H Cros; J H McNeill
Journal:  Am J Physiol       Date:  1989-09

3.  Insulin-like effect of vanadyl ion on streptozotocin-induced diabetic rats.

Authors:  H Sakurai; K Tsuchiya; M Nukatsuka; M Sofue; J Kawada
Journal:  J Endocrinol       Date:  1990-09       Impact factor: 4.286

4.  Vanadate normalizes hyperglycemia in two mouse models of non-insulin-dependent diabetes mellitus.

Authors:  J Meyerovitch; P Rothenberg; Y Shechter; S Bonner-Weir; C R Kahn
Journal:  J Clin Invest       Date:  1991-04       Impact factor: 14.808

5.  In search of predictive markers of remission from insulin dependence in type 1 diabetes: a preliminary report.

Authors:  E Guastamacchia; A Ciampolillo; V Lattanzi; G Lollino; M Rosco; G Lucivero; A Dell'Osso; R Giorgino; G M Nardelli
Journal:  Diabetes Res Clin Pract       Date:  1992-05       Impact factor: 5.602

6.  One-year treatment of streptozotocin-induced diabetic rats with vanadyl sulphate.

Authors:  S Dai; K H Thompson; J H McNeill
Journal:  Pharmacol Toxicol       Date:  1994-02

7.  The protein tyrosine phosphatase inhibitor, pervanadate, is a powerful antidiabetic agent in streptozotocin-treated diabetic rats.

Authors:  A Shisheva; O Ikonomov; Y Shechter
Journal:  Endocrinology       Date:  1994-01       Impact factor: 4.736

8.  Long-term effectiveness of oral vanadyl sulphate in streptozotocin-diabetic rats.

Authors:  M C Cam; R A Pederson; R W Brownsey; J H McNeill
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

9.  Effect of vanadate on elevated blood glucose and depressed cardiac performance of diabetic rats.

Authors:  C E Heyliger; A G Tahiliani; J H McNeill
Journal:  Science       Date:  1985-03-22       Impact factor: 47.728

10.  Orthovanadate both mimics and antagonizes the transforming growth factor beta action on normal rat kidney cells.

Authors:  G Rijksen; M C Völler; E J Van Zoelen
Journal:  J Cell Physiol       Date:  1993-02       Impact factor: 6.384

View more
  2 in total

1.  Heteroleptic oxidovanadium(IV)-malate complex improves glucose uptake in HepG2 and enhances insulin action in streptozotocin-induced diabetic rats.

Authors:  Thanise Pitelli de Nigro; Graciele Cristiane More Manica; Susan Webber de Souza; Carlos Henrique Alves Jesus; Rúbia Camila Ronqui Bottini; Juliana Morais Missina; Glaucio Valdameri; Giovana Gioppo Nunes; Joice Maria da Cunha; Geraldo Picheth; Fabiane Gomes de Moraes Rego
Journal:  Biometals       Date:  2022-07-01       Impact factor: 3.378

2.  Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson's disease mouse model.

Authors:  Yi-Qing Lv; Lin Yuan; Yan Sun; Hao-Wen Dou; Ji-Hui Su; Zhi-Pan Hou; Jia-Yi Li; Wen Li
Journal:  Transl Neurodegener       Date:  2022-03-07       Impact factor: 8.014

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.